KR20250044594A - Pi3키나아제 억제제와 관문 억제제의 조합을 사용하여 다형성 교모세포종 및 유방암을 포함한 기타 암을 선별하고 치료하는 방법 및 제품 - Google Patents
Pi3키나아제 억제제와 관문 억제제의 조합을 사용하여 다형성 교모세포종 및 유방암을 포함한 기타 암을 선별하고 치료하는 방법 및 제품 Download PDFInfo
- Publication number
- KR20250044594A KR20250044594A KR1020247036529A KR20247036529A KR20250044594A KR 20250044594 A KR20250044594 A KR 20250044594A KR 1020247036529 A KR1020247036529 A KR 1020247036529A KR 20247036529 A KR20247036529 A KR 20247036529A KR 20250044594 A KR20250044594 A KR 20250044594A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- combination
- article
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329096P | 2022-04-08 | 2022-04-08 | |
| US63/329,096 | 2022-04-08 | ||
| US202263368499P | 2022-07-15 | 2022-07-15 | |
| US63/368,499 | 2022-07-15 | ||
| PCT/US2023/065433 WO2023196899A2 (en) | 2022-04-08 | 2023-04-06 | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250044594A true KR20250044594A (ko) | 2025-04-01 |
Family
ID=88243701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247036529A Pending KR20250044594A (ko) | 2022-04-08 | 2023-04-06 | Pi3키나아제 억제제와 관문 억제제의 조합을 사용하여 다형성 교모세포종 및 유방암을 포함한 기타 암을 선별하고 치료하는 방법 및 제품 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250228863A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504264A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511969A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250044594A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119654165A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023249640A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255739A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012457A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023196899A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456628A (zh) * | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| RU2016148441A (ru) * | 2014-05-21 | 2018-06-22 | Ф. Хоффманн-Ля Рош Аг | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом |
| US20190038713A1 (en) * | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2020215037A1 (en) * | 2019-04-18 | 2020-10-22 | The Regents Of The University Of Michigan | Combination with checkpoint inhibitors to treat cancer |
| PH12023550160A1 (en) * | 2020-07-31 | 2023-09-18 | Exelixis Inc | Combinations for the Treatment of Cancer |
-
2023
- 2023-04-06 US US18/854,796 patent/US20250228863A1/en active Pending
- 2023-04-06 CA CA3255739A patent/CA3255739A1/en active Pending
- 2023-04-06 CN CN202380044911.1A patent/CN119654165A/zh active Pending
- 2023-04-06 JP JP2024559691A patent/JP2025511969A/ja active Pending
- 2023-04-06 EP EP23785623.2A patent/EP4504264A4/en active Pending
- 2023-04-06 AU AU2023249640A patent/AU2023249640A1/en active Pending
- 2023-04-06 WO PCT/US2023/065433 patent/WO2023196899A2/en not_active Ceased
- 2023-04-06 KR KR1020247036529A patent/KR20250044594A/ko active Pending
-
2024
- 2024-10-07 MX MX2024012457A patent/MX2024012457A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012457A (es) | 2025-03-07 |
| CA3255739A1 (en) | 2023-10-12 |
| WO2023196899A2 (en) | 2023-10-12 |
| JP2025511969A (ja) | 2025-04-16 |
| WO2023196899A9 (en) | 2023-12-21 |
| CN119654165A (zh) | 2025-03-18 |
| AU2023249640A1 (en) | 2024-10-24 |
| US20250228863A1 (en) | 2025-07-17 |
| EP4504264A4 (en) | 2026-03-11 |
| WO2023196899A3 (en) | 2023-11-23 |
| EP4504264A2 (en) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The role of autophagy in cancer: therapeutic implications | |
| Kim et al. | A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma | |
| JP2021143182A (ja) | 癌を治療するためのbtk阻害剤とチェックポイント阻害剤との組合せ | |
| KR101489045B1 (ko) | Pi3k 억제자 및 mek 억제자의 조합 | |
| Liu et al. | Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms | |
| US10959984B2 (en) | Methods for treating cancer with RORγ inhibitors | |
| CN113840606A (zh) | 给药kras抑制剂治疗癌症 | |
| US20200069694A1 (en) | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 | |
| Lee et al. | EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma | |
| JP2020183445A (ja) | 医薬組成物 | |
| JP2021001237A (ja) | がん処置のための組み合わせ療法 | |
| WO2025184572A1 (en) | Wee1 inhibitor combination therapy | |
| Papadopoulou et al. | NLCQ-1 (NSC 709257) Exploiting Hypoxia with a Weak DNA-Intercalating Bioreductive Drug | |
| TW201722422A (zh) | 用於治療癌症之合理組合療法 | |
| US20250228863A1 (en) | Methods and Products to Screen and Treat Glioblastoma Multiforme and Other Cancers, Including Breast Cancers, Using A Combination of PI3KINASE Inhibitors With Checkpoint Inhibitors | |
| Catley et al. | Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly (ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma | |
| KR20250172562A (ko) | 에플로르니틴의 조성물 및 사용 방법 | |
| CA3272623A1 (en) | METHODS OF SCREENING AND TREATMENT OF NON-SMALL CELL LUNG CANCER | |
| US20100256136A1 (en) | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | |
| EP3638236A1 (en) | Methods of treating brain tumors using combination therapy | |
| Alexiou et al. | Systemic chemotherapy in brain gliomas | |
| US20250099426A1 (en) | Indolium Compounds for Treating Cancer | |
| EP4008324A1 (en) | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer | |
| Fang | A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant Tumors | |
| WO2026041090A1 (zh) | DNA烷化剂治疗p53基因突变或缺陷阴性癌症、肿瘤患者 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |